SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$340M
Q3 2024
Positions
79
Filings on Record
25
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Altium Capital Management LLC reported $340M in U.S.-listed holdings across 79 positions for Q3 2024.

Its largest position, VERA, represents 8.9% of the portfolio.

Compared with Q2 2024, the fund opened 32 new positions and exited 21.

Portfolio Metrics

Turnover
+20.4%
vs prior filed quarter
Top-10 Concentration
+47.3%
share of reported value
Largest Position
+8.9%
Vera Therapeutics
New / Exited
32 / 21
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 95.4%Other: 2.9%ADR: 1.5%Equity WRT: 0.2%
  • Common Stock · 95.4% · $324M
  • Other · 2.9% · $10M
  • ADR · 1.5% · $5M
  • Equity WRT · 0.2% · $745,019

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EWEDWARDS LIFESCIENCES CORPNEW+222.0K222.0K+$15M$15M
GKOSGLAUKOS CORPNEW+77.0K77.0K+$10M$10M
MMSIMERIT MED SYS INCNEW+85.0K85.0K+$8M$8M
PCVXVAXCYTE INCNEW+72.0K72.0K+$8M$8M
ARWRARROWHEAD PHARMACEUTICALS INNEW+355.0K355.0K+$7M$7M
IRTCIRHYTHM TECHNOLOGIES INCNEW+86.0K86.0K+$6M$6M
EOLSEVOLUS INCNEW+355.0K355.0K+$6M$6M
ESTAESTABLISHMENT LABS HLDGS INCNEW+131.0K131.0K+$6M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

75 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1VERAVERA THERAPEUTICS INChistory →CL A8.90%$30M684.0K
2ADMAADMA BIOLOGICS INChistory →COM8.00%$27M1.36M
3SRPTSAREPTA THERAPEUTICS INChistory →COM6.25%$21M170.0K
4EWEDWARDS LIFESCIENCES CORPhistory →COM4.31%$15M222.0K
5XENEXENON PHARMACEUTICALS INChistory →COM4.18%$14M360.6K
6ZVRAZEVRA THERAPEUTICS INChistory →COM NEW3.47%$12M1.70M
7INTRA-CELLULAR THERAPIES INCCOM3.32%$11M154.0K
8SOLENO THERAPEUTICS INCCOM3.16%$11M212.9K
9GKOSGLAUKOS CORPhistory →COM2.95%$10M77.0K
10INSMINSMED INChistory →COM PAR $.012.79%$9M130.0K
11MMSIMERIT MED SYS INChistory →COM2.47%$8M85.0K
12RZLTREZOLUTE INChistory →COM NEW2.43%$8M1.70M
13PCVXVAXCYTE INChistory →COM2.42%$8M72.0K
14AVADEL PHARMACEUTICALS PLCCOM SHS2.36%$8M610.0K
15VKTXVIKING THERAPEUTICS INChistory →COM2.35%$8M126.0K
16CN2CATALYST PHARMACEUTICALS INChistory →COM2.25%$8M385.0K
17CTNMCONTINEUM THERAPEUTICS INChistory →CL A2.08%$7M369.1K
18ARWRARROWHEAD PHARMACEUTICALS INhistory →COM2.02%$7M355.0K
19SVRASAVARA INChistory →COM1.97%$7M1.57M
20IRTCIRHYTHM TECHNOLOGIES INChistory →COM1.88%$6M86.0K
21EOLSEVOLUS INChistory →COM1.69%$6M355.0K
22ESTAESTABLISHMENT LABS HLDGS INChistory →COM1.67%$6M131.0K
23RXSTRXSIGHT INChistory →COM1.63%$6M112.0K
24AXSMAXSOME THERAPEUTICS INChistory →COM1.53%$5M58.0K
25SKYESKYE BIOSCIENCE INChistory →COM NEW1.51%$5M1.32M
26XTNTXTANT MED HLDGS INChistory →COM NEW1.48%$5M7.42M
27LRMRLARIMAR THERAPEUTICS INChistory →COM1.34%$5M693.0K
28CAPRCAPRICOR THERAPEUTICS INChistory →COM NEW1.28%$4M285.0K
29LUNGPULMONX CORPhistory →COM1.22%$4M500.0K
30CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW1.18%$4M195.0K
31KROSKEROS THERAPEUTICS INChistory →COM1.18%$4M69.0K
32REALTHE REALREAL INChistory →COM1.17%$4M1.27M
33CATXPERSPECTIVE THERAPEUTICS INChistory →COM NEW1.14%$4M290.0K
34BHVNBIOHAVEN LTDhistory →COM1.10%$4M75.0K
35ORICORIC PHARMACEUTICALS INChistory →COM1.07%$4M355.0K
36GPCRSTRUCTURE THERAPEUTICS INCSPONSORED ADS0.90%$3M70.0K
37OTLKOUTLOOK THERAPEUTICS INCCOM0.85%$3M541.5K
38VCELVERICEL CORPCOM0.85%$3M68.0K
39HELPCYBIN INCCOM NEW0.83%$3M317.0K
40TERNS PHARMACEUTICALS INCCOM0.81%$3M330.0K
41OCGNOCUGEN INCCOM0.69%$2M2.35M
42MLTXMOONLAKE IMMUNOTHERAPEUTICSCLASS A ORD0.59%$2M40.0K
43BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.57%$2M85.0K
44VERU INCCOM0.46%$2M2.03M
45ATRCATRICURE INCCOM0.45%$2M54.0K
46CTMXCYTOMX THERAPEUTICS INCCOM0.32%$1M915.0K
47ENVVENO MEDICAL CORPORATIONCOM0.24%$802,771238.9K
48TEMPEST THERAPEUTICS INCCOM0.22%$763,000545.0K
49PROMIS NEUROSCIENCES INCCOM NEW0.21%$726,744581.4K
50MISTMILESTONE PHARMACEUTICALS INCOM0.20%$668,800440.0K
51KARYOPHARM THERAPEUTICS INCCOM0.18%$614,200740.0K
52UNICYCIVE THERAPEUTICS INCCOM0.18%$600,8371.47M
53FAT BRANDS INC*W EXP 07/16/2020.15%$499,000200.0K
54CELLECTAR BIOSCIENCES INCCOM NEW0.14%$460,100215.0K
55BETTER CHOICE CO INCCOM NEW0.08%$278,215133.1K
56EXPION360 INCCOM0.03%$106,3722.06M
57NXGLWNEXGEL INC*W EXP 12/01/2020.03%$91,474225.0K
58SCPXSCORPIUS HOLDINGS INCCOM0.02%$63,57088.3K
59RCKTWROCKET PHARMACEUTICALS INC*W EXP 09/02/2020.02%$51,209731.6K
60ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.01%$34,000200.0K
61WEARABLE DEVICES LTD*W EXP 09/14/2020.01%$28,0911.41M
62MOBIX LABS INC*W EXP 99/99/9990.01%$22,320150.0K
63CINGWCINGULATE INC*W EXP 12/10/2020.01%$18,684270.0K
64NEKTAR THERAPEUTICSCOM0.00%$14,84511.4K
65NEXALIN TECHNOLOGY INC*W EXP 99/99/9990.00%$8,400105.0K
66BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.00%$6,275250.0K
67VSEEWVSEE HEALTH INC*W EXP 99/99/9990.00%$6,000150.0K
68BTMWQBITCOIN DEPOT INC*W EXP 06/30/2020.00%$2,49550.0K
69JEFFS BRANDS LTD*W EXP 99/99/9990.00%$2,44568.7K
70NLS PHARMACEUTICS LTD*W EXP 02/02/2020.00%$2,280200.0K
71CYCUWWESTERN ACQSTN VENTURES CORP*W EXP 99/99/9990.00%$2,180100.0K
72CONDUIT PHARMACEUTICALS INC*W EXP 09/22/2020.00%$1,595100.0K
73COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$1,41728.3K
74SRZNWSURROZEN INC*W EXP 08/01/2030.00%$1,04482.2K
75TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/10/2020.00%$34318.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.